Abstract: Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject an effective amount of iloprost on demand or as rescue medication (also referred to as pro re nata, PRN), wherein iloprost is administered to the subject via inhalation using a portable soft mist inhaler. In preferred embodiments, the soft mist inhaler is the Respimat™ or the Medspray™ wet aerosol inhaler. A method of treating a patient suffering from pulmonary hypertension, comprising: (a) providing a portable and pre-filled soft mist inhaler adapted for delivering an effective amount of iloprost; and (b) administering to the patient the effective amount of iloprost by inhalation on an as-needed basis.

Abstract: A method for determining contractility independent of load Ees of a ventricle of a person is provided. The chronological profile of blood pressure during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) is first determined for a at least one ventricle over at least one period of a person's heartbeat. The at least one resulting pressure curve is then calibrated and normalized, and then the end-systolic pressure is determined from this calibrated, normalized pressure curve. The profile of blood volume over time is determined during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) for a ventricle over at least one period of a person's heartbeat, to determine the end-systolic volume Ves. The intercept VO is then determined from this end-systolic volume Ves, and contractility independent of load Ees of an examined ventricle of a person is calculated as a slope from the end-systolic pressure Pes, the end-systolic volume Ves, and the intercept V0.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The invention relates to a method for determining contractility independent of load Ees of at least one examined ventricle of a person. The chronological profile of blood pressure during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) is first determined for at least one ventricle over at least one period of a person's heartbeat. The at least one resulting pressure curve is then calibrated and normalized, and then the end-systolic pressure is determined from this calibrated, normalized pressure curve. Furthermore, the profile of blood volume over time is determined during isovolumetric contraction (IVK) and isovolumetric relaxation (IVR) for at least one ventricle over at least one period of a person's heartbeat, to then determine the end-systolic volume Ves therefrom.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Nanoparticles comprising at least three polymers, selected independently of one another from the list comprising PLGA, PLA, TPGS, TPGS-750M, PVA, LAEOLA/PLA-PEO-PLA, and also at least one active ingredient, selected from the list comprising paclitaxel, docetaxel and SB-T-1214. The particles have a core-shell structure, the core containing the at least one active ingredient and at least two polymers, the polymers being selected independently of one another from the list comprising RG502H, RG504, PLA, LAEOLA/PLA-PEO-PLA, TPGS and TPGS-750M, the shell containing PVA and/or TPGS. The nanoparticles are nebulizable.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: The present invention relates to a Statistical method of assessing whether a subject suffers from Cancer or is prone to suffering from Cancer, said method comprising the step of performing at least one Statistical algorithm for Classification and for regression on measurement data of the subject, wherein the measurement data of the subject comprises at least one of the following: a value of GATA6 Em isoform in at least one sample taken from the subject, a value NKX2-1 Em isoform in said at least one sample, a value of GATA6 Ad isoform in said at least one sample, NKX2-1 Ad isoform in said at least one sample; and wherein at least one of the following is used as at least one classifier or a component of at least one classifier in the Statistical method: GATA6 Em isoform, NKX2-1 Em isoform, GATA6 Ad isoform, NKX2-1 Ad isoform, ratio of GATA6 Em isoform/GATA6 Ad isoform, ratio of NKX2-1 Em isoform/NKX2-1 Ad isoform.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.